Business / Finance RSS Feed - Business / Finance

Universal Health Services announces net income of $174.3 million for first quarter 2015

Universal Health Services announces net income of $174.3 million for first quarter 2015

Universal Health Services, Inc. announced today that its reported net income attributable to UHS was $174.3 million, or $1.73 per diluted share, during the first quarter of 2015 as compared to $138.1 million, or $1.38 per diluted share, during the comparable quarter of 2014. [More]
MiMedx Group's revenue increases 108% to $40.8 million in first quarter 2015

MiMedx Group's revenue increases 108% to $40.8 million in first quarter 2015

MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today its record results for the first quarter of 2015. [More]
Intarcia Therapeutics announces closing of $225 million synthetic royalty financing

Intarcia Therapeutics announces closing of $225 million synthetic royalty financing

Intarcia Therapeutics, Inc. today announced the closing of a $225 million synthetic royalty financing with an equity conversion option at a $5.5 billion Company valuation. Plans are to use these funds to accelerate the initiation of additional head-to-head comparative and switch studies of ITCA 650 vs. leading oral and injectable type 2 diabetes therapies. [More]
Boston Scientific, Brainlab form strategic collaboration

Boston Scientific, Brainlab form strategic collaboration

Boston Scientific Corporation announces a collaboration with Brainlab AG, a leading software-driven medical technology company that helps improve patient treatment planning and surgical navigation. [More]

MicroCare Medical Highlights its most Advanced Products at Med-Tech Innovations

One of the newest product updates to be exhibited is MicroCare Duraglide® dry lubricant. Offering unparalleled lubricity, the fast-drying Duraglide® fluids leave a smooth, even, slippery coating on any surface... [More]
Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Resverlogix, Hepalink announce equity investment and license agreement for RVX-208

Resverlogix Corp. today announced that it has entered into a Framework Agreement which sets forth the principal business terms for an equity investment and a license of RVX-208, for all indications, to Shenzhen Hepalink Pharmaceutical Co., Ltd. for China, Hong Kong, Taiwan and Macau (the "Territories"). [More]
Neuronetics completes Series F Financing Round

Neuronetics completes Series F Financing Round

Neuronetics, Inc., the established market leader in transcranial magnetic stimulation (TMS) technology, announced today the completion of its Series F Financing Round, which included investment from GE Ventures, as well as its original investor base totaling $34.3 million. [More]

American Securities signs agreement to acquire Royal Adhesives and Sealants

American Securities LLC and Arsenal Capital Partners today announced that American Securities has partnered with management and signed a definitive agreement to acquire Royal Adhesives and Sealants, LLC, a leading producer of proprietary, high-performance adhesives and sealants, from Arsenal Capital Partners. [More]
Haemonetics' revenue for fourth quarter fiscal 2015 down 6%

Haemonetics' revenue for fourth quarter fiscal 2015 down 6%

Haemonetics Corporation today reported revenue for the fourth quarter fiscal 2015 of $226.5 million, down 6%. Excluding currency impact, revenue was down 4% in the quarter. The Company reported a fourth quarter GAAP net loss of $2.9 million or $0.06 per share. [More]
TWi signs Settlement Agreement with Takeda on patent litigation related to generic Dexilant

TWi signs Settlement Agreement with Takeda on patent litigation related to generic Dexilant

TWi Pharmaceuticals, Inc. today announced that it has entered into a Settlement Agreement with Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals America, Inc. (individually and collectively, "Takeda") to settle and dismiss all outstanding patent litigation related to TWi's generic dexlansoprazole delayed release capsules for oral administration in 30 mg and 60 mg dosage strengths. [More]
OncoGenex terminates agreement with Teva, regains rights to custirsen

OncoGenex terminates agreement with Teva, regains rights to custirsen

OncoGenex Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, OncoGenex Technologies Inc., executed a termination agreement with Teva Pharmaceuticals Ltd. under which OncoGenex will regain rights to custirsen, an investigational compound currently in Phase 3 clinical development as a treatment for prostate and lung cancers. [More]
Natera, LifeLabs sign new agreement for non-invasive prenatal testing in Canada

Natera, LifeLabs sign new agreement for non-invasive prenatal testing in Canada

Natera, Inc., a global leader in non-invasive genetic testing, and LifeLabs Medical Laboratory Services today announced a new agreement that gives LifeLabs the rights to perform non-invasive prenatal testing (NIPT) in Canada using Natera technology. [More]

Lannett amends, increases revolving credit facility from $50 million to $120 million

Lannett Company, Inc. today announced that it has amended and increased its five-year revolving credit facility to $120 million from $50 million. The amended facility includes an accordion feature that will allow the company to increase borrowings by a total of up to an additional $30.0 million, subject to securing additional commitments from existing lenders or new lending institutions. [More]

DATIS, NPS MedicineWise partner to deliver face-to-face educational visits to GPs across South Australia

A new three-year contract launched in Adelaide today will see the Drug and Therapeutics Information Service based at the Repatriation General Hospital continue to deliver NPS MedicineWise educational visiting programs to general practitioners (GPs) across South Australia. [More]

DATIS, NPS MedicineWise partner to deliver face-to-face educational visits to GPs across South Australia

A new three-year contract launched in Adelaide today will see the Drug and Therapeutics Information Service (DATIS) based at the Repatriation General Hospital continue to deliver NPS MedicineWise educational visiting programs to general practitioners (GPs) across South Australia. [More]
Eppendorf launches mobile app

Eppendorf launches mobile app

Eppendorf AG's new app offers a variety of useful aids for everyday laboratory work in addition to product information that has been optimized for mobile devices. [More]

ELC Group signs landmark deal with Chinese pharmaceutical giant

ELC Group, one of the fastest-growing providers of regulatory affairs services, today announces that it has been awarded a 1.5 million Euro contract by one of China’s biggest pharmaceutical companies. [More]
Getinge secures EUR 160 million loan from EIB for development of new medical devices

Getinge secures EUR 160 million loan from EIB for development of new medical devices

The European Investment Bank has provided a EUR 160 million loan to Getinge AB, a global medical technology company, for its research and development in the areas of surgery, intensive care, infection control, care ergonomics and wound care. Getinge’s research addresses unmet medical needs and targets the development of new devices with higher efficiency and safety for increased positive outcomes for both caregivers and patients. [More]

Yorkshire & Humber Academic Health Science Network (AHSN) hosts Medicines Optimisation Roadshow on Tuesday 12 May 2015

The Yorkshire The Yorkshire & Humber Academic Health Science Network (AHSN) will be hosting their Medicines Optimisation Roadshow on Tuesday 12 May 2015. [More]
Alltech enters into agreement to acquire Ridley

Alltech enters into agreement to acquire Ridley

Alltech and Ridley Inc. announced today that they have entered into a plan of arrangement agreement under which Alltech will acquire 100 percent of the outstanding stock of Ridley, one of the leading commercial animal nutrition companies in North America, for CAD $40.75 per share. [More]
Advertisement
Advertisement